The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R21 Clinical Trial Optional)
ID: 356080Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356080

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-012.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R21 Clinical Trial Optional)." This initiative aims to support pilot and exploratory research that investigates the combined effects of cancer and HIV stigma on health outcomes for HIV-positive individuals diagnosed with cancer, with a focus on developing interventions to mitigate these stigmas. The program is particularly relevant for understanding and improving treatment access and health outcomes in populations facing elevated burdens of both HIV and cancer. A total funding of $1 million is anticipated for three awards, each limited to $275,000 over a two-year period, with applications opening on November 13, 2024, and a submission deadline of December 10, 2024. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-CA-25-012-Full-Announcement.html
    RFA-CA-25-012.html
    The National Cancer Institute (NCI), under the Department of Health and Human Services, has announced a funding opportunity (RFA-CA-25-012) titled "The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R21 Clinical Trial Optional)." This is an R21 Exploratory/Developmental Research Grant aimed at supporting research that examines how the combined stigmas of cancer and HIV affect health outcomes in HIV-positive individuals diagnosed with cancer. The initiative seeks to promote innovative pilot studies that assess and address the negative impacts of these stigmas, proposing interventions at multiple levels to enhance cancer care and outcomes. The program is open for applications starting November 13, 2024, with a total funding of $1 million anticipated for three awards, each limited to $275,000 over two years. Applications must consider the intersectionality of various identity-based stigmas and focus on adult populations, particularly in regions with a high burden of HIV and cancer. The call for research reflects an urgent need to understand and mitigate the compounded stigma affecting treatment access, adherence, and overall health outcomes for these vulnerable individuals.
    Similar Opportunities
    The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer," aimed at enhancing research on the intersection of cancer and HIV stigma. This initiative seeks to expand understanding of how these stigmas impact cancer outcomes among HIV-positive individuals, develop interventions to mitigate their negative effects, and promote research in both domestic and international contexts, particularly in regions with high burdens of HIV and cancer. The funding opportunity allows for a maximum project period of five years, with direct costs capped at $500,000 per year, and is open to a diverse range of eligible applicants, including various educational institutions and community organizations. Interested parties must submit their applications by December 10, 2024, and can find additional information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at researching the intersection of cancer stigma and HIV stigma in individuals diagnosed with both conditions. This initiative seeks to advance understanding of how these stigmas affect cancer outcomes among HIV-positive individuals, promote stigma reduction interventions, and encourage research in areas with high HIV-cancer burdens. The NIH plans to award up to six R01 grants, each with a ceiling of $500,000, as part of a total estimated funding pool of $5 million, with the NOFO expected to be published in late Summer 2024 and applications due in late Fall 2024. Interested applicants are encouraged to prepare by reviewing related presentations and materials available online.
    Notice of Intent to Publish a Funding Opportunity Announcement for The confluence of cancer stigma and HIV stigma in HIV-positive individuals diagnosed with cancer (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at exploring the intersection of cancer stigma and HIV stigma in HIV-positive individuals diagnosed with cancer. This initiative seeks to support pilot and exploratory research that enhances understanding of how these dual stigmas affect cancer outcomes and promotes research in both domestic and international contexts, particularly in regions with a high burden of HIV and cancer. The NIH anticipates funding up to three R21 grants, with a total estimated funding of $1,000,000, and the NOFO is expected to be published in late Summer 2024, with applications due in late Fall 2024. Interested applicants are encouraged to prepare by reviewing the initiative's presentation and will find further details on the application process following the NOFO publication.
    Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at reducing HIV-associated stigma to improve prevention, treatment, and care for individuals living with HIV/AIDS in low- and middle-income countries (LMICs). This initiative invites applications for Research Project Grants (R01) to develop and pilot test interventions that address stigma and its impact on health outcomes, particularly focusing on innovative measurement strategies, support for adolescents, and the effects of stigma on caregivers and the aging population. The program emphasizes collaboration between U.S. and LMIC institutions to enhance research capacity and tackle multiple health-related stigmas, including those associated with comorbidities. Eligible applicants can request funding up to $400,000, with a submission deadline of December 22, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-190.html.
    Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)." This initiative aims to support multilevel and multidisciplinary intervention research focused on improving the quality of life and promoting successful aging among individuals living with HIV, particularly those from racial and ethnic minority groups and lower socioeconomic backgrounds. The funding, which ranges from $5-6 million to support approximately 5-6 awards, will provide a maximum budget of $750,000 annually over five years for projects that address social determinants of health and involve community engagement. Interested applicants can find more details and guidelines on the NIH website, with the application process opening on November 11, 2023, and a submission deadline of December 12, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    Co-infection and Cancer (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Co-infection and Cancer (R21 Clinical Trial Not Allowed)" aimed at enhancing research on the mechanisms and epidemiology of co-infections in relation to cancer development. This grant seeks innovative proposals that investigate how co-infections, particularly those involving known oncogenic agents (excluding HIV), may influence carcinogenesis and contribute to cancer disparities among diverse populations. The maximum funding amount available for each application is $275,000 over a two-year period, with applications due by November 16, 2025. Eligible applicants include a wide range of institutions and organizations, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Elucidating Mechanisms Associated with HIV Related Co-Morbidities in Populations Experiencing Health Disparities (R01 - Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Elucidating Mechanisms Associated with HIV Related Co-Morbidities in Populations Experiencing Health Disparities." This initiative aims to support research that investigates the underlying mechanisms contributing to health disparities in HIV and aging, particularly focusing on how multiple comorbidities affect health outcomes and quality of life among individuals from marginalized populations. The program emphasizes a multidisciplinary approach and encourages engagement with community stakeholders to enhance the relevance of the research. Approximately $3 million is available for four awards and $1.5 million for two additional awards for fiscal year 2024, with a project duration of up to five years. Interested applicants can find more information and guidelines at the NIH Grants website and should direct inquiries to grantsinfo@nih.gov. The application deadline is set for January 7, 2026.
    HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research initiatives focused on HIV-associated non-communicable diseases (NCDs) at low- and middle-income country (LMIC) institutions through the R21 Clinical Trial Optional grant. This program aims to support locally relevant research that explores the relationship between HIV infection and the development of NCDs, enhance research capacity, and foster collaborative networks among researchers in LMICs and the U.S. The grant provides funding up to $275,000 over a two-year period, with a submission deadline of December 8, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Institute on Deafness and Other Communication Disorders (NIDCD), has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)." This grant aims to stimulate innovative research addressing critical issues related to communication disorders—such as hearing, balance, taste, smell, voice, speech, and language—specifically for individuals living with HIV/AIDS. The initiative encourages multidisciplinary collaborations and supports low-risk clinical trials that do not require FDA oversight, with a total funding limit of $275,000 for two-year projects, and no more than $200,000 in any single year. Interested applicants, including various academic institutions and nonprofits, must submit their proposals by January 7, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.